Savara Inc. SVRA · Stock Open Savara Inc. in new tab
Savara Inc. Analysis (SVRA)
Is Savara Inc. a good investment? Savara Inc. (SVRA) is currently trading at 5.33 USD. Market analysts have a consensus price target of 10.94 USD. This suggests a potential upside from current levels.
Earnings Schedule: Savara Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.29.
Investor FAQ
Does Savara Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Savara Inc.?
Savara Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -0.56.
Company Profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
| Split Date | Split Ratio to 1 |
|---|---|
| June 11, 2002 | 0.500000 |
| April 26, 2010 | 0.040000 |
| April 28, 2017 | 0.010000 |
Community Discussion